Quinolinic acid in the pathogenesis of Alzheimer's disease

Gilles J. Guillemin*, Kieran R. Williams, Danielle G. Smith, George A. Smythe, Juliana Croitoru-Lamoury, Bruce J. Brew

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

84 Citations (Scopus)

Abstract

We propose that the tryptophan catabolites produced through the kynurenine pathway (KP), and more particularly quinolinic acid (QUIN), may play an important role in the pathogenesis of Alzheimer's disease (AD). In this study, we demonstrated that after 72 hours amyloid peptide (Aβ) 1-42 induced indoleamine 2,3-dioxygenase (IDO) expression and in a significant increase in production of QUIN by human macrophages and microglia. In contrast, Aβ11-40 and Prion peptide (PrP) 106-126 did not induce any significant increase in QUIN production. We also investigated the potential modulatory effect of QUIN and kynurenic acid (KYNA) on Aβ11-42 and Aβ1-40 aggregation. After 24 and 120 hours, we did not observe any significant difference in the level of aggregation compared to the control (Aβ alone). Aβ has been shown to induce IL1-β mRNA expression by human foetal astrocytes and macrophages. We demonstrate that QUIN has the same effect. Interestingly, IL-Iβ has been found in association with plaques in AD. All together these data imply that QUIN may be, locally, one of the factors involved in the pathogenesis of neuronal damage in AD.

Original languageEnglish
Pages (from-to)167-176
Number of pages10
JournalAdvances in Experimental Medicine and Biology
Volume527
Publication statusPublished - 2003
Externally publishedYes

Fingerprint Dive into the research topics of 'Quinolinic acid in the pathogenesis of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this